Home/Pipeline/InterVapor® System (BTVA)

InterVapor® System (BTVA)

Severe Emphysema / COPD (Hyperinflation)

Pivotal (FDA IDE)Active – Pivotal Trial (STEP-UP)

Key Facts

Indication
Severe Emphysema / COPD (Hyperinflation)
Phase
Pivotal (FDA IDE)
Status
Active – Pivotal Trial (STEP-UP)
Company

About Uptake Medical

Uptake Medical is dedicated to transforming the treatment of severe pulmonary diseases through its proprietary vapor ablation platform. Its flagship InterVapor® System is commercially available in key international markets, generating revenue, while U.S. market access remains a pivotal strategic goal pending FDA approval. The company operates as a core subsidiary of Broncus Medical (HKEX: 2216), utilizing this structure for R&D, manufacturing, and commercial expansion across Asia, Europe, and Australia.

View full company profile

About Uptake Medical

Uptake Medical is dedicated to transforming the treatment of severe pulmonary diseases through its proprietary vapor ablation platform. Its flagship InterVapor® System is commercially available in key international markets, generating revenue, while U.S. market access remains a pivotal strategic goal pending FDA approval. The company operates as a core subsidiary of Broncus Medical (HKEX: 2216), utilizing this structure for R&D, manufacturing, and commercial expansion across Asia, Europe, and Australia.

View full company profile

About Uptake Medical

Uptake Medical is dedicated to transforming the treatment of severe pulmonary diseases through its proprietary vapor ablation platform. Its flagship InterVapor® System is commercially available in key international markets, generating revenue, while U.S. market access remains a pivotal strategic goal pending FDA approval. The company operates as a core subsidiary of Broncus Medical (HKEX: 2216), utilizing this structure for R&D, manufacturing, and commercial expansion across Asia, Europe, and Australia.

View full company profile

Therapeutic Areas